Alzheimer's amyloid β interaction with normal human plasma high density lipoprotein:: association with apolipoprotein and lipids

被引:98
作者
Koudinov, AR
Berezov, TT
Kumar, A
Koudinova, NV
机构
[1] Russian Peoples Friendship Univ, Sch Med, Russian Acad Med Sci, Moscow 117198, Russia
[2] Natl Mental Hlth Res Ctr, Neurochem Lab, Moscow 113152, Russia
[3] Inst Biomed Chem, Moscow 109832, Russia
[4] Russian Peoples Friendship Univ, Sch Med, Dept Biochem, Moscow 117198, Russia
[5] NYU Med Ctr, Dept Pathol, New York, NY 10016 USA
[6] NYU Med Ctr, Dept Med, New York, NY 10016 USA
关键词
amyloid beta protein; Alzheimer's disease; apolipoprotein; biotinylation; high density lipoprotein; lipid;
D O I
10.1016/S0009-8981(97)00207-6
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
We report studies of the interaction of Alzheimer's amyloid beta protein (A beta) with normal human plasma high density lipoprotein (HDL), aiming to clarify to which lipoprotein (LP) structural constituent (apolipoprotein or lipid) soluble A beta is primarily bound. Purified HDLs were incubated with biotinylated A beta 1-30 followed by LP repurification by size exclusion (SE) HPLC. SDS-PAGE, immunoblot and N-terminal sequence analysis of the biotin-A beta positive protein bands revealed that A beta is bound to many apolipoproteins of the HDL, mainly apoA-I, apoA-II, apoE and apoJ. On the other hand, reconstituted, protein-free HDL lipid particles also bind A beta peptide and inhibit its aggregation, as intact HDL does. This was assessed by SE-HPLC, SDS-PAGE, immunoblot analysis, ultrastructural electron microscopy and Congo Red staining for beta amyloid fibrils. Our data imply that A beta binding to lipids may play an important role in maintaining the peptide in solution and thus be particularly relevant to A beta normal and pathologic biochemistry and physiology. (C) 1998 Elsevier Science B.V.
引用
收藏
页码:75 / 84
页数:10
相关论文
共 34 条
[1]  
BRADLEY WA, 1988, BIOL CHOLESTEROL, P95
[2]  
BURDICK D, 1992, J BIOL CHEM, V267, P546
[3]  
Davis R.A., 1991, BIOCH LIPIDS LIPOPRO, P403
[4]  
FOLCH J, 1957, J BIOL CHEM, V226, P497
[5]  
FRANGIONE B, 1996, APOLIPOPROTEIN E ALZ, P151
[6]   ALZHEIMERS-DISEASE - INITIAL REPORT OF THE PURIFICATION AND CHARACTERIZATION OF A NOVEL CEREBROVASCULAR AMYLOID PROTEIN [J].
GLENNER, GG ;
WONG, CW .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1984, 120 (03) :885-890
[7]   AGGREGATION AND SECONDARY STRUCTURE OF SYNTHETIC AMYLOID BETA-A4 PEPTIDES OF ALZHEIMERS-DISEASE [J].
HILBICH, C ;
KISTERSWOIKE, B ;
REED, J ;
MASTERS, CL ;
BEYREUTHER, K .
JOURNAL OF MOLECULAR BIOLOGY, 1991, 218 (01) :149-163
[8]   CHARACTERIZATION OF AMYLOID PROTEIN-AA AND PROTEIN-SAA AS APOLIPOPROTEINS OF HIGH-DENSITY-LIPOPROTEIN (HDL) - DISPLACEMENT OF SAA FROM THE HDL-SAA COMPLEX BY APO AI AND APO AII [J].
HUSEBEKK, A ;
SKOGEN, B ;
HUSBY, G .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1987, 25 (04) :375-381
[9]   THE SOLUBLE FORM OF ALZHEIMERS AMYLOID-BETA PROTEIN IS COMPLEXED TO HIGH-DENSITY-LIPOPROTEIN-3 AND VERY HIGH-DENSITY-LIPOPROTEIN IN NORMAL HUMAN PLASMA [J].
KOUDINOV, A ;
MATSUBARA, E ;
FRANGIONE, B ;
GHISO, J .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 205 (02) :1164-1171
[10]  
KOUDINOV A, 1997, CELL BIOL INT, V25, P265